Business
Result of Meeting
Result of Meeting.
About this update from Optibiotix Health Plc
[{"type":"text","content":"\n \nRNS Number : 9408C OptiBiotix Health PLC 25 January 2018 \n\n25 January 2018\nOptiBiotix Health plc\n(\"OptiBiotix\" or the \"Company\")\n \nResult of GM\n \nOptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high\ncholesterol and diabetes, announces that at the General Meeting held earlier today, all resolutions were duly passed.\n \nFor further information, please contact:\n \n\n\n\n\nOptiBiotix Health plc\n\n\nwww.optibiotix.com\n\n\n\n\nStephen O'Hara, Chief Executive\n\n\nContact via Walbrook below\n\n\n\n\n\n\n\n\n\n\n\n\nCairn Financial Advisers LLP (NOMAD)\n\n\nTel: 020 7213 0880\n\n\n\n\nLiam Murray / Jo Turner\n\n\n\n\n\n\n\n \nfinnCap (Broker)\n\n\n \nTel: 020 7220 0500\n\n\n\n\nAdrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)\n\n\n\n\n\n\n\nTony Quirke (Corporate Broking)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR Ltd\n\n\nTel: 020 7933 8780 or [email protected]\n\n\n\n\nAnna Dunphy\n\n\nMob: 07876 741 001\n\n\n\n\n\n\n\n\n\n \n \nAbout OptiBiotix - www.optibiotix.com \n \nOptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.\n \nThe aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. \n \nOptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.\n\nThis information is provided by RNSThe company news service from the London Stock Exchange END ROMLLFSLLEI...